BioZen develops a non‑surgical pharmaceutical treatment for true gynecomastia, a condition that affects more than half of men and often leads to discontinuation of prostate cancer therapies. The company’s lead compound, originally self‑tested by the founder, aims to reduce breast tissue growth without the need for corrective surgery, offering a safer alternative for patients.
Funding
Funding not disclosed
Founders
Product
Problem
True gynecomastia, the enlargement of male breast tissue, frequently leads men undergoing prostate cancer treatment to discontinue life‑saving therapies. More than half of men experience this condition at some point, and the current standard of care is corrective surgery, which carries risks and may be inaccessible.
Solution
BioZen is developing an orally administered, non‑surgical pharmaceutical therapy that specifically targets true gynecomastia. The drug is designed to reduce breast tissue volume, allowing patients to continue essential prostate cancer medications without resorting to surgery. Clinical validation aims to demonstrate efficacy and safety comparable to surgical outcomes while offering a convenient, systemic treatment option. By addressing the underlying hormonal drivers of gynecomastia, the therapy provides a medically approved alternative for men who would otherwise face treatment interruption.
Target Audience
Primary customers are urologists and oncologists treating prostate cancer patients who develop true gynecomastia, as well as endocrinologists managing hormone‑related breast enlargement in men.
Features
- Oral formulation enabling self‑administration without clinical procedures
- Pharmacologic mechanism that selectively reduces glandular breast tissue
- Designed to be compatible with concurrent prostate cancer therapies
- Clinical development program focused on safety, efficacy, and regulatory approval
- Potential to eliminate the need for corrective surgery and associated recovery time